COMP <GO>
EOLS vs BLSM // EV/EBITDA & P/E VALUATION
Evolus Inc. (NASDAQ) VS. BlossomHill Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 2
— BLSM 0
■ METRIC PARITY
LAST: $7.52 (-1.51%) • MKT CAP: $496.7M
valuation
—
LAST: $15.21 (-7.59%) • MKT CAP: $483.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. BLSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EOLS | BLSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.20% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -11.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -17.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 11.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 37.8 | +8.33 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $496.7M | $483.4M | $13.3M | EOLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EOLS REV | BLSM REV | EOLS GROSS % | BLSM GROSS % | EOLS FCF | BLSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $297.2M | $0 | 66.3% | — | -$45.7M | — |
| FY 2024 | $266.3M | — | 68.5% | — | -$19.5M | — |
| FY 2023 | $202.1M | — | — | — | -$34.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
BLSM // BETA —